Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties

被引:19
作者
Caraglia, Michele [1 ]
Dicitore, Alessandra [2 ]
Marra, Monica [1 ]
Castiglioni, Sara [2 ]
Persani, Luca [2 ,3 ]
Sperlongano, Pasquale [4 ]
Tagliaferri, Pierosandro [5 ]
Abbruzzese, Alberto [1 ]
Vitale, Giovanni [2 ,3 ]
机构
[1] Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy
[2] Ist Auxol Italiano IRCCS Milan, Milan, Italy
[3] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[4] Univ Naples 2, Dept Anaesthesiol & Special Surg, I-80138 Naples, Italy
[5] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy
关键词
Type I interferons; interferon-alpha; interferon-beta; STATs; mTOR; pegylated interferons; farnesyltransferase inhibitors; EGF-R; ACTIVATED PROTEIN-KINASE; SERINE PHOSPHORYLATION; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; ANTITUMOR-ACTIVITY; ADJUVANT THERAPY; HEPATITIS-C; IFN-ALPHA; APOPTOSIS; CELLS;
D O I
10.2174/092986613805290372
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-alpha, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-alpha is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
引用
收藏
页码:412 / 423
页数:12
相关论文
共 123 条
[1]
ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085
[2]
The proteasome: structure, function, and role in the cell [J].
Adams, J .
CANCER TREATMENT REVIEWS, 2003, 29 :3-9
[3]
Ubiquitin cross-reactive protein is released by the bovine uterus in response to interferon during early pregnancy [J].
Austin, KJ ;
Ward, SK ;
Teixeira, MG ;
Dean, VC ;
Moore, DW ;
Hansen, TR .
BIOLOGY OF REPRODUCTION, 1996, 54 (03) :600-606
[4]
INTERFERON AFFECTS BOTH G1 AND S+G2 IN CELLS STIMULATED FROM QUIESCENCE TO GROWTH [J].
BALKWILL, F ;
TAYLORPAPADIMITRIOU, J .
NATURE, 1978, 274 (5673) :798-800
[5]
[6]
Human interferons alpha, beta and omega [J].
Bekisz, J ;
Schmeisser, H ;
Hernandez, J ;
Goldman, ND ;
Zoon, KC .
GROWTH FACTORS, 2004, 22 (04) :243-251
[7]
Interferons at age 50: past, current and future impact on biomedicine [J].
Borden, Ernest C. ;
Sen, Ganes C. ;
Uze, Gilles ;
Silverman, Robert H. ;
Ransohoff, Richard M. ;
Foster, Graham R. ;
Stark, George R. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :975-990
[8]
Stat3 activation is required for cellular transformation by v-src [J].
Bromberg, JF ;
Horvath, CM ;
Besser, D ;
Lathem, WW ;
Darnell, JE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (05) :2553-2558
[9]
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo [J].
Bruzzese, F ;
Di Gennaro, E ;
Avallone, A ;
Pepe, S ;
Arra, C ;
Caraglia, M ;
Tagliaferri, P ;
Budillon, A .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :617-625
[10]
Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide [J].
Buechner, SA ;
Wernli, M ;
Harr, T ;
Hahn, S ;
Itin, P ;
Erb, P .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2691-2696